

## Presentation of the proposed Board

### ***The Nomination Committee's proposal for the Board of Directors of BioArctic AB prior to the Annual General Meeting 2023***

#### **NEW ELECTION**

##### **Cecilia Edström (1966)**

Proposed as director:	2023
Holdings in BioArctic:	3,000 B-shares
Education:	Bachelor of Science in Finance and Economics from the Stockholm School of Economics
Other current assignments:	Founder and CEO ceed konsult AB. Board member of Flerie Invest AB, A3P Biomedical AB and Neonode Inc. Advisory Board Member, European Patient Safety Foundation (EUPSF).

Cecilia Edström has a Bachelor of Science in finance and economics from the Stockholm School of Economics. She has more than 30 years of experience from a variety of industries, including life sciences, where she has held several leadership roles including CEO and CFO. Her extensive international experience includes responsibility for strategy, business development, sales, and finance. During her career, Cecilia Edström has held positions at, among others, Bactiguard, TeliaSonera, Scania and SEB and today works as a consultant with a focus on management, business development, communication, and sustainability. Her broad experience, industry knowledge and significant network will add additional valuable competence to the board. Cecilia Edström also has experience from board assignments in both public and private companies in several different sectors, including life science.

Cecilia Edström is independent in relation to the company, its executive management and the major shareholders of the company.

#### **RE-ELECTION**

##### **Eugen Steiner (1954)**

*Proposed chairman of the Board*

Director since:	2017
Holdings in BioArctic:	75,000 B-shares
Education:	Karolinska Institutet (Sweden) (licensed physician, Doctor of Clinical Pharmacology).
Other current assignments:	Chairman of the Board of Spago Nanomedical AB and Empros Pharma AB. Board member of A3P Biomedical AB, Inbox Capital AB, Epiendo Pharmaceuticals ehf. and Stockholm School of Entrepreneurship. Venture partner in HealthCap.

Eugen Steiner is independent in relation to the company, its executive management and the major shareholders of the company.

**Ivar Verner (1947)**

Deputy chairman since: 2017  
Board member since: 2010  
Holdings in BioArctic: 113,770 B-shares privately held and through Förvaltningsaktiebolaget Kanalen AB.  
Education: Master of Business Administration, Stockholm School of Economics, Sweden  
Other current assignments: Chairman of the Board of Erlandsons Brygga AB, Craft Software Holding AB, Craft Software Holding AB and Valsättra Exploaterings AB. Board member of Sehlhall Fastigheter AB.

Ivar Verner is independent in relation to the company, its executive management and the major shareholders of the company.

**Håkan Englund (1952)**

Director since: 2020  
Holdings in BioArctic: -  
Education: Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden.  
Other current assignments: Chairman of the Board of SecureAppbox AB. Board member of Antrad Medical AB and Prostatype Genomics AB. Owner and CEO of JDS Invest AB.

Håkan Englund is independent in relation to the company, its executive management and the major shareholders of the company.

**Pär Gellerfors (1947)**

Director since: 2003  
Holdings in BioArctic: 5,759,988 A-shares and 13,343,201 B-shares through Ackelsta AB.  
Education: Bachelor's degree in chemistry; PhD in chemistry; Associate Professor of Biochemistry, all from Stockholm University, Sweden  
Other current assignments: Founder and CEO of MPG Medical AB. Founder and Board member of Ackelsta AB and LPB Sweden AB.

Pär Gellerfors controls 21.7 percent of the share capital and 32.6 percent of the votes in the company and has previously been active in the company's management. Pär Gellerfors therefore is not independent in relation to the company, its executive management nor the major shareholders of the company.

**Lars Lannfelt (1949)**

Director since: 2003  
Holdings in BioArctic: 8,639,998 A-shares and 20,885,052 B-shares through Demban AB.  
Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.  
Other current assignments: Board member of Demban AB and LPB Sweden AB.

Lars Lannfelt controls 33.5 percent of the share capital and 49.3 percent of the votes in the company and is employed in the company. Lars Lannfelt thereby is not independent in relation to the company, its executive management nor the major shareholders of the company.

**Lotta Ljungqvist (1961)**

Director since: 2021  
Holdings in BioArctic: 3,159  
Education: Degree in biochemistry from KTH Royal Institute of Technology in Stockholm, Sweden. Doctorate in biochemical technology.  
Other current assignments: Board member of Atlas Antibodies AB, Genovis AB, Arocell AB, NorthXBiologics AB and BioLamina AB. Chairman of the Royal Swedish Academy of Engineering Sciences' (IVA) department X Biotechnology and chairman of SwedenBio.

Lotta Ljungqvist is independent in relation to the company, its executive management and the major shareholders of the company.

**Mikael Smedeby (1968)**

Director since: 2018  
Holdings in BioArctic: 27,270 B-shares  
Education: Master of Laws, Uppsala University, Sweden  
Other current assignments: Lawyer and Partner in the law firm Lindahl. Chairman of the board in Coeli Holding AB (including subsidiaries) and Salléngruppen AB. Board member of Rarity Bioscience AB, Sirius Fotboll and Smedeby Förvaltning AB.

Mikael Smedeby is independent in relation to the company, its executive management and the major shareholders of the company.

-----

*The information regarding board assignments and holdings of shares is as of 31 December 2021 and also includes any changes thereafter known to the company.*